Literature DB >> 21672897

The value of banked samples for oncology drug discovery and development.

Peter M Shaw1, Scott D Patterson.   

Abstract

To gain insights into human biology and pathobiology, ready access to banked human tissue samples that encompass a representative cross section of the population is required. For optimal use, the banked human tissue needs to be appropriately consented, collected, annotated, and stored. If any of these elements are missing, the studies using these samples are compromised. These elements are critical whether the research is for academic or pharmaceutical industry purposes. An additional temporal element that adds enormous value to such banked samples is treatment and outcome information from the people who donated the tissue. To achieve these aims, many different groups have to work effectively together, not least of which are the individuals who donate their tissue with appropriate consent. Such research is unlikely to benefit the donors but others who succumb to the same disease. The development of a large accessible human tissue bank resource (National Cancer Institute's Cancer HUman Biobank [caHUB]) that provides an ongoing supply of human tissue for all working toward the common goal of understanding human health and disease has a number of advantages. These include, but are not limited to, access to a broad cross section of healthy and diseased populations beyond what individual collections may achieve for understanding disease pathobiology, therapeutic target discovery, as well as a source of material for diagnostic assay validation. Models will need to be developed to enable fair access to caHUB under terms that enable appropriate intellectual property protection and ultimate data sharing to ensure that the biobank successfully distributes samples to a broad range of researchers.

Entities:  

Mesh:

Year:  2011        PMID: 21672897     DOI: 10.1093/jncimonographs/lgr004

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  10 in total

1.  Donation intentions for cancer genetics research among African Americans.

Authors:  Jasmine A McDonald; Benita Weathers; Frances K Barg; Andrea B Troxel; Judy A Shea; Deborah Bowen; Carmen E Guerra; Chanita Hughes Halbert
Journal:  Genet Test Mol Biomarkers       Date:  2012-01-06

Review 2.  Public-private relationships in biobanking: a still underestimated key component of open innovation.

Authors:  Paul Hofman; Christian Bréchot; Kurt Zatloukal; Georges Dagher; Bruno Clément
Journal:  Virchows Arch       Date:  2013-12-14       Impact factor: 4.064

3.  Intentions to donate to a biobank in a national sample of African Americans.

Authors:  Jasmine A McDonald; Susan Vadaparampil; Deborah Bowen; Gayenell Magwood; Jihad S Obeid; Melanie Jefferson; Richard Drake; Mulugeta Gebregziabher; Chanita Hughes Halbert
Journal:  Public Health Genomics       Date:  2014-06-12       Impact factor: 2.000

4.  Development of tissue bank.

Authors:  R P Narayan
Journal:  Indian J Plast Surg       Date:  2012-05

Review 5.  Impacts of a biobank: Bridging the gap in translational cancer medicine.

Authors:  Tushar Vora; Nirav Thacker
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Jan-Mar

Review 6.  Rare cancers: Challenges & issues.

Authors:  Raveendran K Pillai; K Jayasree
Journal:  Indian J Med Res       Date:  2017-01       Impact factor: 2.375

7.  Standardization developments for large scale biobanks in smoking related diseases - a model system for blood sample processing and storage.

Authors:  Johan Malm; Thomas E Fehniger; Pia Danmyr; Ákos Végvári; Charlotte Welinder; Henrik Lindberg; Paul Upton; Stephanie Carter; Roger Appelqvist; Karin Sjödin; Elisabet Wieslander; Magnus Dahlbäck; Melinda Rezeli; David Erlinge; György Marko-Varga
Journal:  Transl Respir Med       Date:  2013-08-30

Review 8.  Biobanking of human gut organoids for translational research.

Authors:  Francesca Perrone; Matthias Zilbauer
Journal:  Exp Mol Med       Date:  2021-10-18       Impact factor: 8.718

9.  Establishing a Southern Swedish Malignant Melanoma OMICS and biobank clinical capability.

Authors:  Charlotte Welinder; Göran Jönsson; Christian Ingvar; Lotta Lundgren; Håkan Olsson; Thomas Breslin; Akos Végvári; Thomas Laurell; Melinda Rezeli; Bo Jansson; Bo Baldetorp; György Marko-Varga
Journal:  Clin Transl Med       Date:  2013-02-27

10.  An effective multisource informed consent procedure for research and clinical practice: an observational study of patient understanding and awareness of their roles as research stakeholders in a cancer biobank.

Authors:  Silvia Cervo; Jane Rovina; Renato Talamini; Tiziana Perin; Vincenzo Canzonieri; Paolo De Paoli; Agostino Steffan
Journal:  BMC Med Ethics       Date:  2013-07-30       Impact factor: 2.652

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.